Home » Regions » Global News » Quanterix launches Simoa Single Molecule Array technology

Quanterix launches Simoa Single Molecule Array technology

Wednesday, July 31, 2013

Quanterix, a company focused on high definition diagnostics, has launched its Single Molecule Array (Simoa) technology, making it commercially available for the first time on a fully automated platform for research use only. Simoa enables life science researchers to explore biomarkers and pathways with greater sensitivity and precision, allowing the development of new diagnostic tests and improved treatment of diseases in oncology, neurology and cardiology.

“The diagnostic platform is capable of measuring individual proteins at concentrations 1,000 times lower than the best immunoassays available today,” said Paul Chapman, president and chief executive officer of Quanterix. “We believe that this technology will provide deeper insights into human health that will allow diagnosing, treating and monitoring conditions more effectively than ever before.  Furthermore, through Quanterix’ exclusive partnership with bioMérieux, Simoa will be available for clinical and industrial diagnostic applications. The ambition is to rapidly translate new discoveries made in research today into potentially life-saving diagnostic tests benefiting patients.”

Simoa provides the ability to detect, measure and validate both new and existing biomarkers easily and cost effectively at concentrations previously unattainable.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!